Etodin

Quick links to important sections

Etodin

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Etodin

Property Description
Active ingredient Etodolac
Form Tablet (immediate/extended-release), Capsule
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use General pain, inflammation, and fever relief
Origin Synthetic, Acetic acid derivative

What Type of Medicine is Etodin (Etodolac)?

Etodin is a brand name for a prescription medication whose active ingredient is Etodolac, classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Etodolac is a synthetic small molecule belonging to the pyranocarboxylic acid group and is structurally defined as an acetic acid derivative.

This substance functions primarily as a preferential cyclooxygenase-2 (COX-2) inhibitor, an action supported by pharmacological studies demonstrating its targeted effect on inflammatory mediators. This differentiation is important because Etodolac exhibits greater selectivity for the COX-2 enzyme compared to certain older, non-selective NSAIDs, a feature clinically recognized for influencing the drug's overall profile.

Composition and Available Forms of Etodin

The drug is a prescription-only (Rx) medication intended for oral administration, typically available as immediate-release tablets and capsules, or in an extended-release tablet format. The active ingredient, Etodolac, is supplied as a racemic mixture of its active and inactive chemical forms.

The availability of both immediate-release and extended-release preparations is structured to match treatment needs; the extended-release format is specifically engineered to provide prolonged therapeutic levels of Etodolac over a longer duration, reducing the frequency of dosing required for sustained relief.

General Purpose and Core Therapeutic Function

The core purpose of Etodin is to provide symptomatic relief by reducing the body’s production of chemicals that cause discomfort. Etodolac is fundamentally an anti-inflammatory agent, an analgesic (pain reliever), and an antipyretic (fever reducer). These effects are achieved through the inhibition of prostaglandin synthesis, a mechanism that is clinically recognized for effectively diminishing swelling, tenderness, and elevated body temperature associated with inflammatory conditions.

Regulatory References

  1. DailyMed: Etodolac Extended-Release Tablet Labeling

What side effects are possible with Etodin?

Etodin is a nonsteroidal anti-inflammatory drug (NSAID) and carries serious safety warnings established by governmental regulatory authorities.

Serious and Clinically Significant Risks

Official labeling for Etodin includes a Black Box Warning highlighting two critical, potentially fatal risks:

  • Cardiovascular Thrombotic Events: An increased risk of serious cardiovascular events, including myocardial infarction (heart attack) and stroke. This risk may occur early in treatment and may increase with the duration of use and dose.
  • Gastrointestinal Adverse Events: An increased risk of serious gastrointestinal events, including bleeding, ulceration, and perforation of the stomach or intestines. These events can occur without warning symptoms, and the risk is higher in elderly patients.

Etodin is contraindicated for treating pain before or after a Coronary Artery Bypass Graft (CABG) surgery.

Other Safety Concerns

Etodin can also cause or worsen serious conditions, including new onset or worsening hypertension (high blood pressure), heart failure, and kidney or liver damage. Severe skin reactions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) have been reported. Hypersensitivity reactions, including anaphylaxis, are also possible.

Common Side Effects

Adverse reactions reported as common (occurring in 1% to 10% of patients) often involve the gastrointestinal and nervous systems. These include dyspepsia, abdominal pain, constipation, diarrhea, nausea, headache, dizziness, edema (fluid retention), and tinnitus (ringing in the ears).

Population-Specific Notes

  • Elderly patients are at a greater risk for serious gastrointestinal events.
  • Use in late pregnancy (around or after 20 weeks) is restricted due to the potential for fetal harm (premature closure of the ductus arteriosus).

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Etodin

Property Description (As Documented in Official Regulatory Sources)
Documented Overdose Presentations Symptoms include lethargy, drowsiness, nausea, vomiting, and epigastric pain.
Physiological Systems Affected (as stated in label) Potential severe outcomes affect the gastrointestinal system (bleeding), renal system (acute failure), and central nervous system (coma, respiratory depression).
Dose-related or Exposure-related Factors (if applicable) Overdose symptoms are generally described as reversible with supportive care following acute NSAID overdose.
Population-specific Overdose Notes (if applicable) The chance of unwanted effects may increase, especially in elderly patients, following exposure.
Emergency-response statements (as written in official documents) Call Poison Control immediately; management procedures include supportive care, gastric lavage, and activated charcoal administration.
When immediate medical help is required (label-derived phrasing only) Immediate medical attention is required for any suspected overdose. Emergency services must be contacted if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Overdose Classifications (High-Level)

Classification Description (As Defined in Official Documents)
Severity Classification (as defined in official documents) Overdose carries a risk of severe outcomes, including acute renal failure, gastrointestinal bleeding, respiratory depression, and coma.
Regulatory Basis (EMA / FDA / etc.) Information derived from the regulatory sections of the FDA Prescribing Information and NIH MedlinePlus, consistent with SmPC documentation.
Overdose-Context Constraints (as defined in official documents) No specific antidote is known; management is restricted to symptomatic and supportive treatment.

Resulting Overdose Structure

Official Overdose Statements:

  • The onset of overdose may be signaled by signs such as lethargy, drowsiness, nausea, vomiting, and epigastric pain.
  • Severe manifestations documented in regulatory sources include gastrointestinal bleeding (signaled by bloody or tarry stools) and acute renal failure.
  • Immediate medical attention is required for any suspected overdose; contact emergency services immediately for signs of collapse, seizure, or trouble breathing.
  • Management is focused on supportive care as no specific antidote is known; procedures such as gastric lavage and the use of activated charcoal are listed as recognized management measures.

Connection to the Overall Overdose Profile (2–4 sentences): Regulatory documents define the Etodolac overdose profile based on a specific cluster of initial gastrointestinal and central nervous system manifestations. The official guidance strictly mandates that all instances of suspected overdose require immediate medical attention due to the documented risk of life-threatening complications, particularly severe bleeding and renal failure. Management is officially described as symptomatic and supportive, without reliance on a known specific antidote.

Therapeutic Uses of Etodin

What Etodin Treats: Main Uses and Benefits

Etodin (Etodolac) is commonly used to help with symptomatic relief across domains characterized by discomfort and inflammation, assisting patients in managing both chronic conditions and acute, temporary episodes.

The medication is applied across therapeutic areas that include the management of Osteoarthritis, Rheumatoid Arthritis, and various causes of acute pain.

Easing Symptoms and Supporting Function

Etodin is relevant in clinical settings marked by persistent joint discomfort, where it helps address symptom clusters involving tenderness, swelling, and related functional stiffness. It is also used in contexts requiring short-term symptomatic assistance during episodes of sudden discomfort, such as pain arising from traumatic injury or supportive relief for postoperative discomfort. This use is targeted at symptoms within the mild to moderate intensity range.

“The medication may help ease the burden of symptoms that interfere with daily functioning, thereby supporting comfort.”

This focus on symptomatic control offers relief that may assist with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Inflammatory Joint Discomfort

Regulatory References

  1. NIH MedlinePlus Drug Information on Etodolac

Eligibility and Restrictions for Use

This information is strictly based on official regulatory documentation and defines the eligible and non-eligible populations for Etodin (Etodolac).

Populations That Must Not Use Etodin (Contraindications)

Official labeling strictly prohibits the use of Etodin in the following groups:

  • Hypersensitivity History: Individuals with a known allergic reaction (hypersensitivity) to Etodolac or any ingredient in the product.
  • NSAID/Aspirin Allergy: Individuals who have experienced asthma, hives (urticaria), or other allergic-type reactions after taking aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).
  • Coronary Artery Bypass Graft (CABG) Surgery: Patients undergoing treatment for peri-operative pain immediately before or after CABG surgery.
  • Late Pregnancy: Pregnant women at or after 30 weeks gestation.

Eligibility Restrictions and Special Populations

Use is restricted or requires special consideration in other specific populations:

  • Pediatric Patients: The safety and effectiveness of conventional forms have not been established in patients under 18 years of age.
  • Severe Renal Impairment: Use is generally not recommended or is contraindicated in patients with advanced or severe kidney disease due to the potential for further decreased renal function.
  • Lactation: Caution is advised, as it is unknown if the drug is excreted in human milk.
  • Older Adults (Geriatric): Older patients are at a greater risk for serious gastrointestinal and cardiovascular events and may require close monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of Etodin (Etodolac) around pharmacokinetic and pharmacodynamic outcomes, and administration restrictions. Co-administration with anticoagulants (e.g., Warfarin), corticosteroids, or SSRIs/SNRIs results in a pharmacodynamic synergy that increases the risk of serious gastrointestinal bleeding. Etodolac also exhibits pharmacokinetic interactions by reducing the renal clearance of Lithium, which can elevate its plasma levels. This effect is often attributed to the inhibition of renal prostaglandin synthesis.

Simultaneously, co-administration with other NSAIDs, including Ketorolac, is generally not recommended due to the potential for increased adverse events. Etodolac is formally contraindicated for treating perioperative pain associated with Coronary Artery Bypass Graft (CABG) surgery. When taken with ACE-inhibitors or ARBs, Etodolac may diminish their antihypertensive effect, increasing the risk of renal function deterioration, especially in volume-depleted or elderly patients. Timing restrictions also apply: the label specifies that NSAIDs should not be used for 8–12 days following the administration of Mifepristone. Finally, taking immediate-release Etodolac with food can reduce its peak plasma concentration (Cmax) by approximately 50 percent, while consumption of alcohol increases the risk of stomach bleeding.

Mechanism of Action

How Etodin Works: Mechanism of Action

Etodin exerts its physiological action by acting as a selective inhibitor primarily targeting the Cyclooxygenase-2 (COX-2) enzyme. This enzyme is critically involved in the synthesis of specific chemical messengers called prostaglandins within the arachidonic acid pathway.

The drug's mechanism involves binding to the active site of the COX-2 enzyme, thereby preventing the enzyme from catalyzing the conversion of its substrate. This molecular blockade leads to a subsequent reduction in the local and systemic production of prostaglandins, which are key mediators in cellular signaling.

This downstream reduction in prostaglandin synthesis modifies the sensitivity of peripheral nociceptors (nerve endings that relay sensation) and alters signaling dynamics within the body's thermoregulation systems. These changes in peripheral nerve sensitization and hypothalamic influence constitute the drug's fundamental physiological action, contributing to decreased nerve signaling and the ability to influence elevated body temperature.

Dosage and Administration Information

How Etodin is Used: Official Administration Guidelines

Etodin, which contains the active ingredient Etodolac, is strictly approved for oral administration using either immediate-release (IR) or extended-release (ER) formulations. Its usage is governed by administration patterns that define how much is taken and how often, based on the specific condition being addressed.

Dosing and Frequency Patterns

Usage Context Form Typical Dosing Regimen Maximum Daily Dose
Acute Pain IR 200 mg to 400 mg every 6 to 8 hours 1000 mg
Chronic Arthritis (OA/RA) IR 300 mg two to three times daily, or 400–500 mg twice daily 1000 mg
Chronic Arthritis (OA/RA) ER 400 mg to 1000 mg once daily 1000 mg

Official instructions emphasize a core principle of using the lowest effective dose for the shortest duration necessary to achieve goals. For chronic conditions, the total daily dose is intended to be adjusted downward once a satisfactory response is established, typically observed within two weeks of initiation.


Administration Conditions and Specific Populations

Etodolac may be taken with or after food or a full glass of water, as food does not significantly affect the total extent of drug absorption, a condition provided for patient comfort. A key procedural requirement is that the extended-release tablets must be swallowed whole and must not be crushed, broken, or chewed.

In terms of population-specific rules, the Extended-Release formulation is approved for use in pediatric patients (ages 6 to 16) for Juvenile Rheumatoid Arthritis, with the dose calculated based on body weight. For older adults, while no dosage adjustment is universally required based on pharmacokinetics, careful adherence to the lowest effective dose principle is recommended.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Etodin

Evidence for Use in Osteoarthritis

The research into Etodin for Osteoarthritis (OA) primarily relies on randomized controlled trials (RCTs). These are studies used in research exploring how symptoms change over time and involved comparison across study groups. Researchers examined patient-reported outcomes describing perceived discomfort and activity level in adult populations diagnosed with OA. Findings describe patterns observed in the studies related to changes in measured pain intensity and changes in functional ability scores during the observed study periods. The overall assessment of symptoms by patients and physicians was frequently reported as a primary outcome measurement in controlled trials. The long-term characteristics of the measured outcomes are not fully established for this chronic condition, as most controlled trials focused on short-term symptom relief.


Evidence for Use in Rheumatoid Arthritis

Etodin was studied for the management of symptoms associated with Rheumatoid Arthritis (RA), a condition characterized by fluctuating or episodic manifestations. The evidence includes both intermediate-term controlled trials and some longer-term studies that were observed for outcomes linked to inflammatory or irritative states. Researchers monitored objective measures such as the tender and swollen joint counts alongside patient-reported outcomes describing perceived discomfort. A distinct area of research was evaluated in specific pediatric populations (children ages 6 to 16 years) with Juvenile Rheumatoid Arthritis (JRA); however, the volume of data for this group remains low relative to the adult data.


Evidence for Use in Acute Pain Management

Research has explored the use of Etodin in conditions associated with acute or disruptive episodes, such as pain following minor surgery. This evidence is derived mainly from single-dose, placebo-controlled, randomized trials. These studies focused on outcomes describing episodic or acute changes. Researchers monitored the time to initial measured change and the total pain change measured over short, defined time intervals. The recorded use of supplementary pain medication was also observed during the study period, contributing to understanding symptom patterns in acute settings.

Frequently Asked Questions (FAQ)

Common questions about Etodin (FAQ)


Q: What is the main reason doctors prescribe Etodin?

According to official product information, Etodin (Etodolac) is approved for the management of the signs and symptoms associated with osteoarthritis and rheumatoid arthritis. It is also indicated for the management of acute pain in adults.


Q: How quickly do people usually start to feel the effects of Etodin?

Studies on the immediate-release formulation indicate that analgesic (pain-relieving) effects may be demonstrated starting within approximately 30 minutes after taking a single dose. For chronic conditions, it may take longer to observe a satisfactory response.


Q: How long does one dose of Etodin typically stay in your system?

Official information regarding the drug's metabolism indicates that Etodin's active component, Etodolac, has a plasma elimination half-life that averages 7.3 hours in healthy adults. The half-life describes the time taken for the amount of the drug in the body to decrease by half.


Q: Is it okay to take Etodin if I already take a vitamin supplement?

Regulatory documents list interactions with specific medications but do not generally address common vitamin supplements. Official information recommends disclosing all medications, vitamins, and herbal products to a healthcare provider.


Q: How is Etodin different from other medications used for the same purpose?

Etodin is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by inhibiting an enzyme called Cyclooxygenase-2 (COX-2). Official information indicates that the drug exhibits a preferential inhibition of COX-2, which is a key pharmacological feature noted in its official profile.


Q: Is Etodin known to cause drowsiness or affect energy levels?

Official regulatory information lists somnolence (drowsiness) and dizziness as reported side effects, occurring in less than 1% of patients. There is no specific information addressing general changes to energy levels.


Q: Is there any research evidence showing how Etodin affects long-term use?

Clinical trials examining chronic conditions have observed patient outcomes over intermediate-term periods. Official information indicates that the drug’s long-term safety is monitored through post-marketing surveillance.


Q: Can older adults safely take Etodin?

Official information indicates that older adults have a greater risk for serious side effects, particularly those affecting the gastrointestinal and cardiovascular systems. Use of the lowest effective dose principle is noted in regulatory guidelines for this population.


Q: Is Etodin generally appropriate for use in children?

The extended-release formulation is approved for use in pediatric patients aged 6 to 16 years for Juvenile Rheumatoid Arthritis (JRA). However, the safety and effectiveness of the conventional immediate-release tablets have not been established in children under 18 years of age.


Q: What should I avoid eating or drinking while using Etodin?

Regulatory guidelines state that the co-consumption of alcohol increases the risk of serious stomach bleeding. Additionally, taking the immediate-release tablet with food can reduce the rate of absorption of the drug.


Q: Do you have to take Etodin indefinitely, or is it usually for a limited time?

Etodin is approved for both acute pain management, which is generally for a limited time, and for the long-term management of chronic conditions like arthritis. The required duration of use is determined by the condition being addressed.


Q: Can Etodin cause weight gain or weight loss?

Official adverse reaction reports indicate the drug can cause edema (fluid retention), which may be linked to unexplained weight gain. General changes in weight are also listed as a less common side effect.


Q: What are the specific signs of an allergic reaction to Etodin?

Signs of a hypersensitivity reaction (allergy) may include hives (urticaria), asthma, swelling of the face or throat (angioedema), and a severe, whole-body reaction called anaphylaxis.


Q: What is the purpose of the warning label about operating heavy machinery while on Etodin?

Patients are cautioned when driving or operating machinery because common side effects reported in official documents include dizziness, somnolence (drowsiness), and blurred vision. These effects can potentially impair a person's ability to perform tasks requiring focus.


Q: Why do doctors check patient history before prescribing Etodin?

The medical review of patient history is necessary to identify specific contraindications and risk factors, such as prior NSAID allergy or recent Coronary Artery Bypass Graft (CABG) surgery. This ensures the drug is used under appropriate circumstances.


Q: Is the severity of side effects from Etodin related to the dose taken?

Yes, official regulatory documents state that the risk of serious adverse effects, including cardiovascular and gastrointestinal events, may increase with the dose and duration of use. For this reason, official dosing recommendations note the importance of using the lowest effective dose for the shortest time necessary.


Q: Can people with high blood pressure use Etodin?

Etodin can cause new onset or worsening hypertension (high blood pressure) and may interfere with the action of blood pressure medications. Official information indicates that blood pressure may need to be closely monitored when the drug is used in this population.


Q: What happens if I miss a scheduled dose of Etodin?

Information for a missed dose generally describes that if a dose is remembered soon after, it can be taken. If it is close to the time of the next dose, the missed dose is typically skipped, and the schedule continues. Official guidelines state to avoid taking two doses at the same time.


Q: Does Etodin affect sleep patterns?

Regulatory documents list insomnia (the inability to sleep) as a less common side effect associated with the use of Etodin.


Q: Can Etodin cause mood changes or unusual feelings?

Reported side effects, occurring in less than 1% of patients, include depression, nervousness, and confusion.


Q: Is a metallic taste in the mouth a known side effect of Etodin?

Official adverse reaction reports include a less common side effect described as 'taste perversion', which encompasses changes in how things taste, such as a metallic sensation.


Q: Does Etodin cause issues with dental health?

Less common side effects noted in regulatory documents include ulcerative stomatitis (mouth ulcers) and dry mouth.


Q: Is there a generic version of Etodin available?

Yes, the active ingredient in Etodin, which is Etodolac, is widely available in generic formulations.


Q: What is the risk of dependence or addiction with Etodin?

Etodin is a Nonsteroidal Anti-inflammatory Drug (NSAID). According to the DEA, it is not classified as a controlled substance and is not associated with a known risk of dependence or addiction.


Q: Does Etodin interact with common over-the-counter cold medicines?

Official regulatory guidelines warn specifically against taking Etodin with other NSAIDs, which are often found in some over-the-counter cold and flu preparations. Regulatory documents recommend consulting a healthcare provider before combining Etodin with any other medicines.


Q: Can Etodin affect the results of lab tests (like blood work)?

Yes, regulatory information indicates that Etodin can potentially affect some lab results. It may cause a false-positive reaction for specific tests measuring urinary bilirubin and ketone bodies. It is also linked to a small decrease in serum uric acid levels.


Q: Can Etodin cause vision changes?

Less common side effects reported in official documents include blurred vision and transient visual disturbances.


Q: Does Etodin affect fertility or sexual function?

Animal studies have shown no impairment of fertility in male or female rats. The official documents do not contain specific information regarding the effects on human sexual function.


Q: Is Etodin a controlled substance in any region?

No, Etodin (Etodolac) is an NSAID and is not listed under the US Controlled Substances Act, nor is it typically classified as a controlled substance in other major regions.

How should Etodin be stored and disposed of?

Official Storage and Disposal Instructions for Etodolac

Requirement Official Condition (Regulatory Basis)
Storage Temperature Store at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F).
Protection Keep from freezing, and protect the product from moisture and excessive heat.
Container Rule Keep in a tightly closed, well-closed container.
Child Safety Must be kept strictly out of the reach of children.

Storage conditions are designed to maintain the product's stability until its expiration date. The official labeling specifies that unused or expired Etodolac should be disposed of by following authorized procedures. This typically involves using a drug take-back program. If a take-back option is unavailable, the medicine must be prepared for disposal in the household trash by mixing it with an undesirable substance, then sealing and discarding it. Flushing the medication is not recommended.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Etodin found in:

A-Z Index: